In additional preclinical work with ABT-737, an agent with similar activity to navitoclax, successful elimination of blasts in AML cell lines and patient samples was accompanied by eradication of BCL-2-dependent leukemia stem cells while sparing normal hematopoietic stem cells which rely on MCL1 for survival7. The gene discussed is BCL2; the disease is acute myeloid leukemia.